PRL and neoplasm: This systematic review supports the use of a combination of a dopamine agonist with an aromatase inhibitor for a subgroup of male patients with prolactinoma, as the addition of anastrozole or letrozole improved the control of prolactin levels and may lead to shrinkage in tumor sizes.